



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Frontiers Production Office,
production.office@frontiersin.org

SPECIALTY SECTION
This article was submitted to
Pharmacology of Anti-Cancer Drugs,
a section of the journal
Frontiers in Pharmacology

RECEIVED 07 November 2022
ACCEPTED 07 November 2022
PUBLISHED 22 November 2022

CITATION
Frontiers Production Office (2022),
Erratum: Efficacy and safety evaluations
of anlotinib in patients with advanced
non-small cell lung cancer treated
with bevacizumab.
Front. Pharmacol. 13:1092147.
doi: 10.3389/fphar.2022.1092147

COPYRIGHT
© 2022 Frontiers Production Office.
This is an open-access article
distributed under the terms of the
[Creative Commons Attribution License
\(CC BY\)](#). The use, distribution or
reproduction in other forums is
permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original
publication in this journal is cited, in
accordance with accepted academic
practice. No use, distribution or
reproduction is permitted which does
not comply with these terms.

Erratum: Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab

Frontiers Production Office*

Frontiers Media SA, Lausanne, Switzerland

KEYWORDS

anlotinib, non-small cell lung cancer (NSCLC), bevacizumab, efficacy, safety

An Erratum on Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab

by Jiang F, Li J, Kong X, Sun P and Qu H (2022). *Front. Pharmacol.* 13:973448. doi: 10.3389/fphar.2022.973448

Due to a mistake on the publisher's part, this article was originally published as a Systematic Review instead of Original Research.

The publisher apologizes for this error and states that this does not change the scientific conclusions of the article in any way. The original article has been updated.